Peptide library
Semaglutide
Approved product
Randomized evidence
Evidence record
- Product and route
- This entry covers subcutaneous Wegovy injection.
- Approval scope
- Wegovy injection: weight management in eligible adults.
- Mechanism
- Activates the GLP-1 receptor.
- Evidence
- Randomized trials.
- Limits
- Check other products separately.
- Safety context
- Severe or persistent gastrointestinal symptoms: contact a clinician.
A reading exercise
When reading a page about semaglutide, choose one sentence that promises a change and underline exactly what would have to be measured. Then look for that measure in the linked source. A phrase such as feeling better leaves you with a different question from a named score recorded at a stated time. Write the source's question in your own words, keeping its measure and timing intact. Put the page's claim beside it. If the two sentences ask different questions, mark the gap rather than filling it with an assumption. Your finished note should say what evidence would connect them.
Questions to take away
- What exact measure would be needed to check the sentence you underlined?
- Does the linked source measure that outcome at the time the page describes?
- Which part of the page's claim remains unanswered by that measure?
Sources
Each date identifies a source check. It is separate from this page’s publication date.
- WEGOVY — NLM; checked
- Wegovy approval — FDA; checked